Drug Details
General Information of the Drug (ID: DR7139) | ||||
---|---|---|---|---|
Name |
AMD3100
|
|||
Synonyms |
Plerixafor; 110078-46-1; Mozobil; AMD3100; 1,4-Bis((1,4,8,11-tetraazacyclotetradecan-1-yl)methyl)benzene; Amd 3100; bicyclam JM-2987; plerixafor (amd3100); Plerixafor hydrochloride; AMD-3100; SDZ SID 791; JM3100; JM 3100; 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane; JM-3100; UNII-S915P5499N; JKL 169; CHEMBL18442; 1,1'-[1,4-Phenylenebis(methylene)]bis-1,4,8,11-tetraazacyclotetradecane; S915P5499N; SID791; 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane]; Mozobil (TN); plerixaforum; Plerixafor [USAN:INN:BAN]; 1,1'-[1,4-phenylenebis(methylene)]bis(1,4,8,11-tetraazacyclotetradecane); Plerixafor 8HCl; GNA & AMD-3100; HHA & AMD-3100; JM 2987; Plerixafor(AMD3100); 1,4,8,11-Tetraazacyclotetradecane, 1,1'-[1,4-phenylenebis(methylene)]bis-, hydrochloride (1:8); Plerixafor-d4 (deuterated); SCHEMBL19038; GTPL844; cc-304; Plerixafor (JAN/USAN/INN); AOB5591; DTXSID70869520; AMD-3100 (CXCR4); CHEBI:125354; BCPP000104; BCP02337; C28H54N8; EX-A1762; ANW-73610; BDBM50035696; MFCD05662218; NSC754363; NSC761388; s8030; ZINC22443609; 1,1'-{1,4-phenylenebis(methylene)}-bis{1,4,8,11-tetraaza-cyclotetradecane}; AKOS005266706; CCG-269710; CS-0451; DB06809; NSC-754363; NSC-761388; NCGC00165722-01; NCGC00165722-02; NCGC00165722-03; 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Galanthus nivalis agglutinin (GNA); AC-26837; AK-41732; AS-42504; HY-10046; AB0009909; FT-0660392; FT-0673966; A25446; D08971; S-7677; AB01566900_01; 078P461; A809618; L000104; Q905835; SR-01000941593; J-503718; SR-01000941593-1; 11''''-xylyl bis-1,4,8,11-tetraazacyclotetradecane; BRD-K33240821-367-01-8; Z2196779619; 1,1''''-{1,4-phenylenebis(methylene)}-bis{1,4,8,11-tetraaza-cyclotetradecane}; 1,1'-(benzene-1,4-diyldimethanediyl)bis(1,4,8,11-tetraazacyclotetradecane); 1,1'[1,4-phenylene-bis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane; 1,4,8,11-Tetraazacyclotetradecane, 1,1'-(1,4-phenylenebis(methylene))bis-; 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Hippeastrum hybrid agglutinin( HHA); 1,4,8,11-tetraazacyclotetradecanyl[4-(1,4,8,11-tetraazacyclotetradecanylmethyl)phenyl]methane; 1,4,8,11-tetraazacyclotetradecanyl[4-(1,4,8,11-tetraazacyclotetradecanylmethyl)phenyl]methane(8HBr.2H2O); 1-({4-[(1,4,8,11-tetraazacyclotetradecan-1-yl)methyl]phenyl}methyl)-1,4,8,11-tetraazacyclotetradecane; 1-{[4-(1,4,8,11-tetraazacyclotetradecan-1-ylmethyl)phenyl]methyl}-1,4,8,11-tetraazacyclotetradecane; 11-{4-[4,8, 11-1,4,8,11tetraaza-cyclotetradec-1-ylmethyl]-benzyl}-1,4,8,11tetraaza-cyclotetradecane-1,4,8-tricarboxylic acid tri-tert-butyl ester
Click to Show/Hide
|
|||
Molecular Type |
Small molecule
|
|||
Disease | Acute lymphoblastic leukemia [ICD-11: 2B33] | Approved | [1] | |
Structure |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
Formula |
C28H54N8
|
|||
PubChem CID | ||||
Canonical SMILES |
C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3
|
|||
InChI |
1S/C28H54N8/c1-9-29-15-17-31-13-3-21-35(23-19-33-11-1)25-27-5-7-28(8-6-27)26-36-22-4-14-32-18-16-30-10-2-12-34-20-24-36/h5-8,29-34H,1-4,9-26H2
|
|||
InChIKey |
YIQPUIGJQJDJOS-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 110078-46-1
|
|||
ChEBI ID | ||||
TTD Drug ID | ||||
DrugBank ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
Triptolide | Tripterygium hypoglaucum | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | BIRC5 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | CBY1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | ERK1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | ERK2 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | MMP-2 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | MMP-9 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | MYC | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | PARP1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | STAT3 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
||
In-vitro Model | MG-63 | CVCL_0426 | Osteosarcoma | Homo sapiens | ||
U2OS | CVCL_0042 | Osteosarcoma | Homo sapiens | |||
SaOS-2 | CVCL_0548 | Osteosarcoma | Homo sapiens | |||
143B | CVCL_2270 | Osteosarcoma | Homo sapiens | |||
HOS-8603 | Osteosarcoma | Homo sapiens | ||||
Experimental
Result(s) |
AMD3100 combined with triptolide can reduce proliferation and metastasis, and induce apoptosis of U2OS cells, which may be related to the Erk1/2, Akt, STAT3 and NF-KappaB pathways. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | C-X-C chemokine receptor 4 (CXCR4) | Molecule Info | [3] | |
KEGG Pathway | Cytokine-cytokine receptor interaction | Click to Show/Hide | ||
2 | Chemokine signaling pathway | |||
3 | Endocytosis | |||
4 | Axon guidance | |||
5 | Leukocyte transendothelial migration | |||
6 | Intestinal immune network for IgA production | |||
7 | Pathways in cancer | |||
NetPath Pathway | IL2 Signaling Pathway | Click to Show/Hide | ||
2 | IL4 Signaling Pathway | |||
3 | Leptin Signaling Pathway | |||
Panther Pathway | Axon guidance mediated by Slit/Robo | Click to Show/Hide | ||
2 | Inflammation mediated by chemokine and cytokine signaling pathway | |||
Pathway Interaction Database | S1P3 pathway | Click to Show/Hide | ||
2 | CXCR4-mediated signaling events | |||
3 | Syndecan-4-mediated signaling events | |||
4 | HIF-1-alpha transcription factor network | |||
5 | Ephrin B reverse signaling | |||
Reactome | Binding and entry of HIV virion | Click to Show/Hide | ||
2 | Chemokine receptors bind chemokines | |||
3 | G alpha (i) signalling events | |||
WikiPathways | GPCRs, Class A Rhodopsin-like | Click to Show/Hide | ||
2 | Hematopoietic Stem Cell Differentiation | |||
3 | HIV Life Cycle | |||
4 | Cardiac Progenitor Differentiation | |||
5 | Peptide GPCRs | |||
6 | GPCR ligand binding | |||
7 | GPCR downstream signaling |